Gattefossé launches three new pharmaceutical excipients

To ensure their international launch and success, Labrafac MC60, Gelucire 59/14 and Emulfree Duo conform to all regulatory requirements
Read Article

Gattefossé has announced the launch of three new pharmaceutical ingredients: Labrafac MC60 and Gelucire 59/14, for the oral administration route and Emulfree Duo for the topical administration route.

In a statement, the company said that with the launch of these three excipients, Gattefossé demonstrates its commitment to exploring the very best of nature and science since 1880.

Launching three ingredients in the same year is unusual in the pharmaceutical ingredient industry, given the long and complex research and development and regulatory demands that are placed on the developer. But once completed, new ingredients can successfully and safely address many formulation challenges that are present in the industry, the statement said.

It also said that to ensure their international launch and success, Labrafac MC60, Gelucire 59/14 and Emulfree duo conform to all regulatory requirements.

“This last quarter of 2021 is both exciting and challenging. We are proud to launch three new lipidic excipients, expand our range and offer new solutions to address our customers’ needs. With everything we do, we always look to innovate, while remaining dedicated to providing solid customer support and technical assistance. As specialists in lipid chemistry, we provide formulation expertise supported by our reliable, effective and safe ingredients,” said Eduardo de Purgly, Chief Executive Officer, Gattefossé group.

Emulfree DuoGattefosséGelucire 59/14Labrafac MC60pharmaceutical excipients
Comments (0)
Add Comment